Sara Verdura

1.9k total citations
52 papers, 1.3k citations indexed

About

Sara Verdura is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Sara Verdura has authored 52 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 18 papers in Oncology and 15 papers in Cancer Research. Recurrent topics in Sara Verdura's work include Epigenetics and DNA Methylation (11 papers), Cancer, Hypoxia, and Metabolism (9 papers) and Cancer, Lipids, and Metabolism (7 papers). Sara Verdura is often cited by papers focused on Epigenetics and DNA Methylation (11 papers), Cancer, Hypoxia, and Metabolism (9 papers) and Cancer, Lipids, and Metabolism (7 papers). Sara Verdura collaborates with scholars based in Spain, United States and Argentina. Sara Verdura's co-authors include Javier A. Menéndez, Elisabet Cuyàs, Begoña Martı́n-Castillo, Joaquim Bosch‐Barrera, Jorge Joven, Joan Brunet, José Antonio Encinar, Melchor Sánchez-Martínez, Salvador Fernández‐Arroyo and Alfons Nonell‐Canals and has published in prestigious journals such as Nature Communications, Cancer Research and Oncogene.

In The Last Decade

Sara Verdura

50 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sara Verdura Spain 20 728 288 270 166 145 52 1.3k
Sung Hoo Jung South Korea 24 772 1.1× 392 1.4× 310 1.1× 141 0.8× 104 0.7× 86 1.5k
Chuan‐Ming Xie China 18 738 1.0× 187 0.6× 185 0.7× 83 0.5× 100 0.7× 42 1.3k
Partha P. Banerjee United States 28 918 1.3× 211 0.7× 183 0.7× 347 2.1× 132 0.9× 58 1.8k
Sabarish Ramachandran United States 18 1.3k 1.8× 398 1.4× 590 2.2× 168 1.0× 189 1.3× 37 1.9k
Miyong Yun South Korea 22 1.1k 1.5× 300 1.0× 370 1.4× 103 0.6× 207 1.4× 53 1.5k
Altaf Mohammed United States 27 888 1.2× 661 2.3× 471 1.7× 139 0.8× 178 1.2× 96 1.9k
Lizhu Lin China 19 633 0.9× 255 0.9× 202 0.7× 177 1.1× 106 0.7× 75 1.2k
Julian C. Desmond United States 18 1.0k 1.4× 260 0.9× 138 0.5× 87 0.5× 109 0.8× 25 1.7k
Huan He China 26 686 0.9× 214 0.7× 177 0.7× 193 1.2× 74 0.5× 65 1.5k
Clotilde Wiel Sweden 18 1.2k 1.7× 281 1.0× 442 1.6× 172 1.0× 239 1.6× 35 1.9k

Countries citing papers authored by Sara Verdura

Since Specialization
Citations

This map shows the geographic impact of Sara Verdura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Verdura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Verdura more than expected).

Fields of papers citing papers by Sara Verdura

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Verdura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Verdura. The network helps show where Sara Verdura may publish in the future.

Co-authorship network of co-authors of Sara Verdura

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Verdura. A scholar is included among the top collaborators of Sara Verdura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Verdura. Sara Verdura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martı́n-Castillo, Begoña, et al.. (2025). Metabolic hallmarks of trastuzumab resistance. Expert Opinion on Therapeutic Targets. 29(7). 457–479. 1 indexed citations
2.
Cuyàs, Elisabet, Sara Verdura, George Kemble, et al.. (2025). Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer. Neoplasia. 62. 101143–101143. 7 indexed citations
3.
Menéndez, Javier A., Ruth Lupu, Begoña Martı́n-Castillo, et al.. (2025). Mitochondrial priming in therapy-induced senescence: implications for CAR-T/NK immunosenolytic therapy. Frontiers in Immunology. 16. 1695244–1695244.
4.
Verdura, Sara, Eva Martinez‐Balibrea, Joaquim Bosch‐Barrera, et al.. (2025). Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies. Cell Death Discovery. 11(1). 91–91. 3 indexed citations
5.
Vila, E., Sara Verdura, José Antonio Encinar, et al.. (2024). 1039P Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy. Annals of Oncology. 35. S697–S697. 1 indexed citations
6.
Verdura, Sara, José Antonio Encinar, Antonio Segura‐Carretero, et al.. (2022). Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors. Cancers. 14(24). 6101–6101. 8 indexed citations
7.
Cuyàs, Elisabet, Salvador Fernández‐Arroyo, Sara Verdura, et al.. (2022). Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells. Cancers. 14(24). 6214–6214. 3 indexed citations
8.
Verdura, Sara, José Antonio Encinar, Salvador Fernández‐Arroyo, et al.. (2022). Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells. International Journal of Molecular Sciences. 23(17). 9986–9986. 4 indexed citations
9.
Verdura, Sara, Elisabet Cuyàs, Verónica Ruiz-Torres, et al.. (2021). Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals. 14(6). 559–559. 40 indexed citations
10.
Tramonti, Angela, Elisabet Cuyàs, José Antonio Encinar, et al.. (2021). Metformin Is a Pyridoxal-5′-phosphate (PLP)-Competitive Inhibitor of SHMT2. Cancers. 13(16). 4009–4009. 19 indexed citations
11.
Bosch‐Barrera, Joaquim, Ariadna Roqué, M. Carmen Carmona-García, et al.. (2021). Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. Pharmaceuticals. 15(1). 19–19. 4 indexed citations
12.
Bosch‐Barrera, Joaquim, Sara Verdura, J.C. Ruffinelli, et al.. (2021). Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. Cancers. 13(16). 4168–4168. 11 indexed citations
13.
Schroeder, Barbara, Ingrid Espinoza, Zeng Hu, et al.. (2021). Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. Cell Death and Disease. 12(11). 977–977. 62 indexed citations
14.
Romero, Octavio A., Juan J. Alburquerque-Béjar, Antonio Gómez, et al.. (2021). SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nature Communications. 12(1). 4319–4319. 36 indexed citations
15.
Menéndez, Javier A., Adriana Papadimitropoulou, Elisabet Cuyàs, et al.. (2021). Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. Cancers. 13(5). 1132–1132. 33 indexed citations
16.
Papadimitropoulou, Adriana, Luciano Vellón, Ella Atlas, et al.. (2020). Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer. International Journal of Molecular Sciences. 21(20). 7737–7737. 10 indexed citations
17.
Cuyàs, Elisabet, Sara Verdura, Begoña Martı́n-Castillo, et al.. (2020). Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. Cancers. 12(7). 1757–1757. 19 indexed citations
18.
Cuyàs, Elisabet, Sara Verdura, Laura Llorach-Parés, et al.. (2018). Metformin directly targets the H3K27me3 demethylase KDM6A/UTX. Aging Cell. 17(4). e12772–e12772. 64 indexed citations
19.
Cuyàs, Elisabet, et al.. (2018). Mitostemness. Cell Cycle. 17(8). 918–926. 18 indexed citations
20.
Verdura, Sara, Ilse Zondervan, Federica Facchinetti, et al.. (2015). PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion. Cancer Research. 75(7). 1287–1297. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sung Hoo Jung Breakdown of academic impact, for papers by Chuan‐Ming Xie Breakdown of academic impact, for papers by Partha P. Banerjee Breakdown of academic impact, for papers by Sabarish Ramachandran Breakdown of academic impact, for papers by Miyong Yun Breakdown of academic impact, for papers by Altaf Mohammed Breakdown of academic impact, for papers by Lizhu Lin Breakdown of academic impact, for papers by Julian C. Desmond Breakdown of academic impact, for papers by Huan He Breakdown of academic impact, for papers by Clotilde Wiel
Rankless by CCL
2026